Description

Anastrozole 1 mg

Marque : Magnus Pharmaceuticals
Contenu : 30 tablets | 1 mg per tablet
Prix : €35
Fabriqué en : L'Europe

🧪 Aperçu du produit

Anastrozole 1 mg is a third-generation non-steroidal aromatase inhibitor (AI) designed to suppress peripheral estrogen synthesis via competitive inhibition of the CYP19 enzyme. Widely used in endocrine and oncology research, it allows for precise estrogen-reduction modeling, testosterone-to-estradiol (T:E) modulation, and post-cycle therapy simulations.

Its long half-life (~46–50 hours) supports once-daily dosing, and the film-coated tablets offer logistical advantages over injectables in hormone-regulation studies. With high selectivity and oral bioavailability, anastrozole is a key tool in studies of male hypogonadism, fertility, and body recomposition protocols.

✅ Principaux résultats de la recherche

Selective aromatase blockade:
Inhibits CYP19 to suppress peripheral estrogen by ≥80% in vivo [DrugBank, NCBI]

Extended half-life:
Elimination t½ ≈ 46–50 hours supports consistent once-daily sampling [PubChem, Wikipedia]

T:E ratio modulation:
1 mg/day improved testosterone-to-estradiol ratios and semen metrics in male trials [PMC]

Body recomposition support:
Reduced systemic estrogen helps prevent gynecomastia and sustain lean-mass retention [Verywell Health]

Room-temperature stability:
Film-coated tablets store safely ≤25 °C — no cold-chain required [Mayo Clinic]

🧬 Applications suggérées en laboratoire

Aromatase inhibition and estrogen-suppression studies
Post-cycle therapy and hormonal recovery research
T:E ratio modulation in hypogonadal or fertility trials
Anti-estrogen support in anabolic-steroid modeling
Oncology research in estrogen-dependent tumors

📊 Spécifications techniques

Champ d'application	Données
Nom chimique	Anastrozole
Formule chimique	C<sub>17</sub>H<sub>19</sub>N<sub>5</sub>
Synonymes	Arimidex, ICI D1033, CP-65787, α,α,α′-Tris(1H-1,2,4-triazol-1-yl-m-tolyloxy)-m-xylene
Poids moléculaire	293.37 g/mol
Numéro CAS	120511-73-1
Demi-vie	46–50 hours
Fenêtre de détection	Medium-to-long (varies with dose and sampling)
Avantages documentés	↓ estrogen >80%, ↑ T:E ratio, ↓ recurrence of ER+ breast cancer
Principaux risques	Arthralgia, hot-flushes, lipid shifts, bone-density reduction
Composé actif total	30 mg per carton (1 mg × 30 tablets)
Durée de conservation	36 months (manufacturer specification)

❄️ Perspectives de recherche soutenues par PubChem

Suppresses peripheral estrogen synthesis by over 80%
Increases T:E ratio in hypogonadal males and fertility models
Demonstrated efficacy in reducing recurrence of estrogen-dependent cancers
Supports lean tissue retention and gynecomastia control
Extended half-life allows single daily dosing for consistent hormonal regulation

⚠️ Effets secondaires documentés par la recherche

Joint pain, bone mineral density reduction, hot-flushes
Altered lipid profiles (↓ HDL, ↑ LDL) in chronic use
Cardiovascular strain risk with long-term administration
Insomnia and mood shifts in estrogen-sensitive models

🧯 Manipulation et conformité

Réservé à la recherche — Not for human or veterinary use
Store at 15–25 °C, protect from moisture and light
Purchase confirms qualified researcher status
Inscrit sur la liste WADA Prohibited List S4 — any exposure may result in a positive anti-doping test